Abstract
e16315 Background: Pancreatic cancer prevalence is on the rise, particularly among octogenarians—individuals aged 80 years and above. This age group, however, remains notably underrepresented in clinical trials, hindering the applicability of findings to this growing demographic. Methods: We conducted a retrospective study investigating the predictive potential of the E-frailty Index (EFI) in relation to chemotherapy tolerance in octogenarian patients with unresectable/metastatic pancreatic adenocarcinoma. Drawing from EFI's developmental insights in a prior study¹, our cohort comprised 72 octogenarians undergoing chemotherapy. Results: Despite a modest statistical correlation (R = 0.038, p = 0.751), our study revealed a weak, but positive association between EFI and chemotherapy toxicity. Conclusions: Our findings, while subtle, highlight the potential relevance of EFI in predicting chemotherapy outcomes among octogenarians. The non-significant correlation underscores the need for larger-scale, prospective trials to confirm these insights. Inconclusion, This study, rooted in the developmental continuum of EFI, offers a glimpse into its potential significance in predicting chemotherapy tolerance in octogenarian pancreatic cancer patients. The call for prospective trials is evident, especially considering the underrepresentation of this demographic in current research.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
